Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction
- PMID: 40436468
- DOI: 10.1016/j.jacc.2025.04.032
Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction
Keywords: ASCVD; Lp(a); lipoprotein(a); prevention.
Conflict of interest statement
Funding Support and Author Disclosures Dr Blankstein has received research support and consulting fees from Amgen and Novartis. Dr Nasir serves on advisory boards for Amgen, Regeneron, and Merck Sharp & Dolme; and his research is partly supported by grants from National Institutes of Health, Patient-Centered Outcomes Research Institute, Novartis, and Ionis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous